{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:54:20Z","timestamp":1784138060407,"version":"3.55.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>\n                      <jats:underline>Background:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>Dupilumab, an interleukin (IL)-4 receptor-\u03b1 inhibitor that blocks IL-4 and IL-13 signaling pathways, is an effective and well-tolerated therapy for moderate-to-severe atopic dermatitis (AD). However, an increased incidence of dupilumab-associated conjunctivitis has been reported in patients treated with dupilumab. In contrast, upadacitinib, a selective Janus kinase 1 inhibitor, is reported to have lower incidence of conjunctivitis than dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Objective:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>The aim of this retrospective study was to investigate ocular adverse events in adult patients with moderate-to-severe AD treated with upadacitinib after discontinuing treatment with dupilumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Methods:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>In total, 33 patients were examined at the start of treatment with upadacitinib after discontinuation of dupilumab, then again after 4 weeks and every 12 weeks up to a maximum of 72 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Results:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>Among the patients in the study, 14 had developed dupilumab-associated conjunctivitis during dupilumab treatment and had complete resolution of ocular symptoms after the switch to upadacitinib within the 1-month follow-up visit. In addition, only 1 patient treated with upadacitinib developed an episode of conjunctivitis. This condition was of mild severity and it spontaneously resolved quickly. Interestingly, this patient had no history of dupilumab-associated conjunctivitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Conclusions:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>All patients who developed dupilumab-associated conjunctivitis experienced complete remission on upadacitinib and only 3% of the patients in our sample developed conjunctivitis after the start of treatment with upadacitinib. In light of this, upadacitinib appears to be a prudent and safe treatment option for AD patients with uncontrolled ocular symptoms associated with dupilumab therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/derm.2022.0063","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T10:49:56Z","timestamp":1674730196000},"page":"445-447","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Ocular Adverse Events in Patients with Atopic Dermatitis Treated with Upadacitinib: A Real-Life Experience"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-0322","authenticated-orcid":false,"given":"Federica","family":"Gelato","sequence":"first","affiliation":[{"name":"From the *Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"From the *Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"From the *Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cavaliere","sequence":"additional","affiliation":[{"name":"From the *Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"From the *Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"From the *Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"issue":"24","key":"e_1_3_1_3_2","first-page":"2335","article-title":"SOLO 1 and SOLO 2 investigators","volume":"375","author":"Simpson EL","year":"2016","unstructured":"Simpson EL, , Bieber T, , Guttman-Yassky E, et al. SOLO 1 and SOLO 2 investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med, 2016; 375(24):2335\u20132348. doi: 10.1056\/NEJMoa1610020.","journal-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med"},{"issue":"12","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"e1021","DOI":"10.1111\/jdv.18427","article-title":"Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks","volume":"36","author":"Mastorino L","year":"2022","unstructured":"Mastorino L, , Cantafio Du\u00f2 VL, , Vecco C, et al. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks. J Eur Acad Dermatol Venereol, 2022; 36(12):e1021\u2013e1023. doi: 10.1111\/jdv.18427.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14080"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17981"},{"issue":"3","key":"e_1_3_1_8_2","first-page":"201","article-title":"Italian DADReL (dupilumab atopic dermatitis in real life) study group","volume":"30","author":"Nettis E","year":"2020","unstructured":"Nettis E, , Bonzano L, , Patella V, et al. Italian DADReL (dupilumab atopic dermatitis in real life) study group. dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol, 2020; 30(3):201\u2013204. doi: 10.18176\/jiaci.0481.","journal-title":"dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol"},{"issue":"6","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum Y","year":"2020","unstructured":"Nahum Y, , Mimouni M, , Livny E, et al. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol, 2020; 104(6):776\u2013779. doi: 10.1136\/bjophthalmol-2019-315010.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1111\/ijd.16022","article-title":"Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?","volume":"61","author":"Mastorino L","year":"2022","unstructured":"Mastorino L, , Ortoncelli M, , Avallone G, et al. Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?. Int J Dermatol, 2022; 61(10):e370\u2013e372. doi: 10.1111\/ijd.16022.","journal-title":"Int J Dermatol"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.7573\/dic.2020-2-3","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab","volume":"9","author":"Ferreira S","year":"2020","unstructured":"Ferreira S, , Torres T. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs Context, 2020; 9:2020-2-3. doi: 10.7573\/dic.2020-2-3.","journal-title":"Drugs Context"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"issue":"7","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"e15575","DOI":"10.1111\/dth.15575","article-title":"Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis","volume":"35","author":"Hayama K","year":"2022","unstructured":"Hayama K, , Fujita H. Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis. Dermatol Ther, 2022; 35(7):e15575. doi: 10.1111\/dth.15575.","journal-title":"Dermatol Ther"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2022.0063","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2022.0063","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2022.0063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:06:51Z","timestamp":1777399611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2022.0063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10,1]]}},"alternative-id":["10.1089\/derm.2022.0063"],"URL":"https:\/\/doi.org\/10.1089\/derm.2022.0063","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]}}}